Wall Street Analysts Turn Bullish on 3 Promising Biotech Stocks (Buy Ratings)
Analysts see big upside in UroGen, Rapport, and Milestone, driven by strong drugs, upcoming data, and underestimated market potential.
/ 31 items
#XY Analyst Up/Down↓
Wolfe Research Initiates Coverage on Palisade Bio and Avalo Therapeutics with Strong Buy Calls
Wolfe Research: PALI “Outperform” ($7) eyes 2027 ulcerative colitis trial; AVTX “Outperform” ($48) waits May LOTUS Phase 2 readout.
Wall Street Goes Bullish on Two Biotech Stocks: INBX and MPLT
Stifel & Needham back INBX & MPLT: promising cancer & brain drugs, strong safety, big market potential.
Stifel Sees 134% Upside in Summit Therapeutics as Ivonescimab Eyes $200B Market
Stifel rates Summit Therapeutics a Buy. Its new cancer drug looks promising, and strong trial results could send the stock much higher.
Gilead’s $5B Tubulis Deal Validates ADC Space – Bullish for Sutro Biopharma
Leerink sees major tailwind for Sutro Biopharma and initiates coverage with $38 price target.
Bio-Rad Faces Headwinds as Citi Downgrades Shares to Neutral
Citi downgrades Bio-Rad to Neutral, citing weak chromatography growth and China market risks; price target cut to $300.